FDA Grants Fast Track Designation to Lantern Pharma’s AI-Enhanced Drug LP-184 for Glioblastoma
Lantern Pharma Inc., an AI company pioneering cancer therapies, announces that the FDA has granted Fast Track Designation for its investigational drug, LP-184, to treat Glioblastoma. Currently in a Ph ...